Identification

Name
Vorinostat
Accession Number
DB02546  (EXPT02902)
Type
Small Molecule
Groups
Approved, Investigational
Description

Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors. A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs. [Wikipedia]

Structure
Thumb
Synonyms
  • Octanedioic acid hydroxyamide phenylamide
  • SAHA
  • SHH
  • Suberanilohydroxamic acid
  • Suberoylanilide hydroxamic acid
  • Vorinostatum
External IDs
MK-0683 / MK0683
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZolinzaCapsule100 mgOralMerck Ltd.2009-06-29Not applicableCanada
ZolinzaCapsule100 mg/1OralMerck Sharp & Dohme Limited2006-10-06Not applicableUs
International/Other Brands
Zolinza
Categories
UNII
58IFB293JI
CAS number
149647-78-9
Weight
Average: 264.3202
Monoisotopic: 264.147392516
Chemical Formula
C14H20N2O3
InChI Key
WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
IUPAC Name
N-hydroxy-N'-phenyloctanediamide
SMILES
ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

Pharmacology

Indication

For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized.

TargetActionsOrganism
AHistone deacetylase 1
inhibitor
Human
AHistone deacetylase 2
inhibitor
Human
AHistone deacetylase 3
inhibitor
Human
AHistone deacetylase 6
inhibitor
Human
UHistone deacetylase 8Not AvailableHuman
UAcetoin utilization proteinNot AvailableAquifex aeolicus (strain VF5)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

71%

Metabolism

The major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by β-oxidation. Human serum levels of two metabolites, O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP).

Route of elimination

In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP). Vorinostat is eliminated predominantly through metabolism with less than 1% of the dose recovered as unchanged drug in urine, indicating that renal excretion does not play a role in the elimination of vorinostat. However, renal excretion does not play a role in the elimination of vorinostat.

Half life

2 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Vorinostat.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Vorinostat.Approved, Investigational
AcenocoumarolVorinostat may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Vorinostat.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vorinostat.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Vorinostat.Experimental
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Vorinostat.Experimental, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Vorinostat.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Vorinostat.Approved
AmiodaroneVorinostat may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AnagrelideVorinostat may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideVorinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherVorinostat may increase the QTc-prolonging activities of Artemether.Approved
AsenapineVorinostat may increase the QTc-prolonging activities of Asenapine.Approved
AzithromycinVorinostat may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Vorinostat.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Vorinostat.Investigational
BedaquilineVorinostat may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Vorinostat.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Vorinostat.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Vorinostat.Investigational, Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorinostat.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Vorinostat.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Vorinostat.Experimental
CeritinibVorinostat may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineVorinostat may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineVorinostat may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Vorinostat.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Vorinostat.Experimental
CiprofloxacinVorinostat may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideVorinostat may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramVorinostat may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinVorinostat may increase the QTc-prolonging activities of Clarithromycin.Approved
ClorindioneVorinostat may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Vorinostat is combined with Clozapine.Approved
CrizotinibVorinostat may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vorinostat.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Vorinostat.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Vorinostat.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vorinostat.Approved
DicoumarolVorinostat may increase the anticoagulant activities of Dicoumarol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Vorinostat.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vorinostat.Approved
DiphenadioneVorinostat may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideVorinostat may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.Approved, Investigational
DofetilideVorinostat may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronVorinostat may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneVorinostat may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DronedaroneVorinostat may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolVorinostat may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Vorinostat.Approved
EliglustatVorinostat may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.Approved
ErythromycinVorinostat may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramVorinostat may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Ethyl biscoumacetateVorinostat may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Vorinostat.Approved, Investigational
FlecainideVorinostat may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluindioneVorinostat may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineVorinostat may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolVorinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
Gadobenic acidVorinostat may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinVorinostat may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Vorinostat.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Vorinostat.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Vorinostat.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Vorinostat.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Vorinostat.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Vorinostat.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Vorinostat.Approved
GoserelinVorinostat may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronVorinostat may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Vorinostat.Investigational
HaloperidolVorinostat may increase the QTc-prolonging activities of Haloperidol.Approved
IbutilideVorinostat may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneVorinostat may increase the QTc-prolonging activities of Iloperidone.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Vorinostat.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Vorinostat.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Vorinostat.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Vorinostat.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Vorinostat.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Vorinostat.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Vorinostat.Experimental
LenvatinibVorinostat may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideVorinostat may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinVorinostat may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Vorinostat.Approved
LopinavirVorinostat may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineVorinostat may increase the QTc-prolonging activities of Lumefantrine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Vorinostat.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat.Approved
MethadoneVorinostat may increase the QTc-prolonging activities of Methadone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Vorinostat.Experimental
MifepristoneMifepristone may increase the QTc-prolonging activities of Vorinostat.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Vorinostat.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Vorinostat.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Vorinostat.Approved, Investigational
MoxifloxacinVorinostat may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Vorinostat.Approved, Investigational
NilotinibVorinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OfloxacinVorinostat may increase the QTc-prolonging activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Vorinostat.Experimental, Investigational
OndansetronVorinostat may increase the QTc-prolonging activities of Ondansetron.Approved
OuabainOuabain may decrease the cardiotoxic activities of Vorinostat.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Vorinostat.Approved, Vet Approved
PaliperidoneVorinostat may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatVorinostat may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PazopanibVorinostat may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineVorinostat may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenVorinostat may increase the QTc-prolonging activities of Perflutren.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Vorinostat.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Vorinostat.Approved, Investigational, Withdrawn
PhenindioneVorinostat may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonVorinostat may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PimozideVorinostat may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Vorinostat.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Vorinostat.Approved, Investigational
PrimaquineVorinostat may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideVorinostat may increase the QTc-prolonging activities of Procainamide.Approved
PromazineVorinostat may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneVorinostat may increase the QTc-prolonging activities of Propafenone.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Vorinostat.Experimental
QuetiapineVorinostat may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineVorinostat may increase the QTc-prolonging activities of Quinidine.Approved
QuinineVorinostat may increase the QTc-prolonging activities of Quinine.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Vorinostat.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Vorinostat.Approved, Investigational
SaquinavirVorinostat may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Vorinostat.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Vorinostat.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Vorinostat.Investigational
SotalolVorinostat may increase the QTc-prolonging activities of Sotalol.Approved
SulfisoxazoleVorinostat may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Vorinostat.Approved, Investigational
TelavancinVorinostat may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinVorinostat may increase the QTc-prolonging activities of Telithromycin.Approved
TetrabenazineVorinostat may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineVorinostat may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TioclomarolVorinostat may increase the anticoagulant activities of Tioclomarol.Experimental
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Vorinostat.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Vorinostat.Approved
ToremifeneVorinostat may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Vorinostat.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Vorinostat.Investigational, Withdrawn
Valproic AcidValproic Acid may increase the thrombocytopenic activities of Vorinostat.Approved, Investigational
VandetanibVorinostat may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibVorinostat may increase the QTc-prolonging activities of Vemurafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Vorinostat.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinVorinostat may increase the anticoagulant activities of Warfarin.Approved
ZiprasidoneVorinostat may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolVorinostat may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Oral administration with a high-fat meal resulted in an increase (33%) in the extent of absorption and a modest decrease in the rate of absorption (Tmax delayed 2.5 hours) compared to the fasted state.

References

Synthesis Reference

Vinayak G. Gore, Madhukar S. Patil, Rahul A. Bhalerao, Hemant M. Mande, Sandeep G. Mekde, "PROCESS FOR THE PREPARATION OF VORINOSTAT." U.S. Patent US20110263712, issued October 27, 2011.

US20110263712
General References
  1. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE: Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006 Aug;5(8):1967-74. [PubMed:16928817]
External Links
Human Metabolome Database
HMDB15568
PubChem Compound
5311
PubChem Substance
46508989
ChemSpider
5120
BindingDB
19149
ChEBI
45716
ChEMBL
CHEMBL98
Therapeutic Targets Database
DAP001082
PharmGKB
PA164748224
HET
SHH
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vorinostat
ATC Codes
L01XX38 — Vorinostat
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
1c3s / 1t69 / 1zz1 / 3c0z / 4bz6 / 4lxz / 4qa0 / 4qa2 / 4r7l / 5eei

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentUveal Melanoma1
1Active Not RecruitingTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Neoplasm1
1Active Not RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Primary Cutaneous B-Cell Non-Hodgkin Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Non-Hodgkin Lymphoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Nasopharyngeal Undifferentiated Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Undifferentiated Carcinoma / Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v71
1Active Not RecruitingTreatmentAdult Solid Neoplasm1
1Active Not RecruitingTreatmentAdvanced Cancers2
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1Active Not RecruitingTreatmentLiver Cancer1
1Active Not RecruitingTreatmentLocally Advanced Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentStage III Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx1
1CompletedNot AvailableLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Lymphomas / Malignant Neoplasm of Pancreas / Melanoma / Multiple Myeloma (MM)1
1CompletedOtherLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Promyelocytic Leukemia (M3) / Blastic Phase Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAcute Promyelocytic Leukemia (APL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Secondary Acute Myeloid Leukemia / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentAdvanced Breast Cancer1
1CompletedTreatmentAdvanced Cancer Refractory / Advanced Cancer Relapsed1
1CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Relapsing Chronic Myelogenous Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentBrain Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Neoplasms Metastasis1
1CompletedTreatmentCancer, Advanced3
1CompletedTreatmentCancers1
1CompletedTreatmentChildhood Acute Promyelocytic Leukemia (M3) / Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Neuroblastoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Extra-Adrenal Paraganglioma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Spinal Cord Neoplasm / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Medulloepithelioma / Childhood Meningioma / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Oligodendroglioma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentEsophageal Cancers / Liver Cancer / Malignant Neoplasm of Stomach1
1CompletedTreatmentGlioblastomas1
1CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia, Myelocytic, Acute Myelodysplastic Syndromes / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Prostate Cancer / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLocalized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentMalignant Lymphomas4
1CompletedTreatmentMalignant Lymphomas / Neuroblastomas / Sarcomas / WilmsTumor1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
1CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Neoplasm of Pancreas / Periampullary Adenocarcinoma1
1CompletedTreatmentMalignant Solid Tumours / Non Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma1
1CompletedTreatmentMetastatic Brain Tumors1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentPelvic Cancer / Radiotherapy1
1CompletedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage III Colon Cancer / Stage III Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1CompletedTreatmentTumors2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific6
1Enrolling by InvitationDiagnosticVon Hippel-Lindau Disease1
1RecruitingBasic ScienceAlzheimer's Disease (AD)1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Carcinoma / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentGrade 3a Follicular Lymphoma / Grade 3b Follicular Lymphoma / Recurrent Classical Hodgkin Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Classical Hodgkin Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma1
1RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
1RecruitingTreatmentLeukemias1
1RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentMalignant Solid Tumours1
1RecruitingTreatmentNeuroblastomas1
1RecruitingTreatmentRenal Cell Adenocarcinoma / Urinary Bladder Neoplasms1
1RecruitingTreatmentTumors, Central Nervous System1
1TerminatedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1TerminatedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Neoplasm1
1TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentBladder Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Non-small Cell Lung, Prostate, Bladder/Urothelial Cancers / Prostate Cancer / Transitional Cell Carcinoma1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Recurrent Anal Cancer / Recurrent Breast Cancer / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Non-small Cell Lung Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Anal Cancer / Stage IV Breast Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1TerminatedTreatmentMalignant Lymphomas1
1TerminatedTreatmentMalignant Solid Tumours1
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentNeoplasms1
1Unknown StatusNot AvailableCancer, Breast1
1WithdrawnTreatmentAdvanced Cancers1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAcute erythroid leukemia / Acute Megakaryoblastic Leukemia / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Ring Sideroblasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ring Sideroblasts / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Cognitive Side Effects of Cancer Therapy / Cognitive/Functional Effects1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Brain Stem Gliomas / Childhood Glioblastoma / Giant Cell Glioblastoma / Gliosarcoma / Untreated Childhood Anaplastic Astrocytoma / Untreated Childhood Anaplastic Oligoastrocytoma / Untreated Childhood Brain Stem Glioma / Untreated Childhood Giant Cell Glioblastoma / Untreated Childhood Gliosarcoma1
1, 2Active Not RecruitingTreatmentAnaplastic Gliomas / Glioblastoma Multiforme1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentChildren With Relapsed Solid Tumor, Lymphoma or Leukemia1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1, 2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharynx Carcinoma / Recurrent Salivary Gland Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage III Major Salivary Gland Carcinoma / Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage III Nasopharyngeal Carcinoma / Stage IV Nasopharyngeal Carcinoma / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1, 2Active Not RecruitingTreatmentRelapsed/Refractory Sarcomas / Tumors, Solid1
1, 2Active Not RecruitingTreatmentStage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2CompletedTreatmentAcute HIV Infection1
1, 2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentBrain Cancer / Malignant Gliomas / Recurrent Glioblastoma1
1, 2CompletedTreatmentCancer, Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2CompletedTreatmentGlioblastomas / Neoplasms, Brain1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
1, 2CompletedTreatmentHistone Deacetylase Inhibitor / Malignant Neoplasm of Stomach1
1, 2CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
1, 2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
1, 2CompletedTreatmentMale Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentMalignant Lymphomas2
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentMyelodysplastic Syndromes1
1, 2CompletedTreatmentNeimann-Pick Disease1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMelanoma / Skin Neoplasms1
1, 2RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentSarcomas1
1, 2SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentBrain Cancer / Glioblastoma Multiforme1
1, 2TerminatedTreatmentCancer, Breast / Neoplasms Metastasis1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Peritoneal Neoplasm1
1, 2TerminatedTreatmentCutaneous Lymphomas / Cutaneous T-Cell Lymphoma (CTCL)1
1, 2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1, 2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentNeoplasms, Ovarian1
1, 2TerminatedTreatmentPeripheral T-Cell Non-Hodgkin's Lymphoma1
1, 2TerminatedTreatmentRecurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2TerminatedTreatmentRefractory Lymphomas / Relapsed Lymphomas1
1, 2TerminatedTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1, 2TerminatedTreatmentStage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1, 2Unknown StatusTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1, 2Unknown StatusTreatmentCancer, Breast1
1, 2WithdrawnTreatmentMalignant Pleural Mesothelioma (MPM)1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD) / Neoplasms, Hematologic / Non-Neoplastic Hematologic and Lymphocytic Disorder1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdult Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia-1 / Chronic Myelomonocytic Leukemia-2 / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
2Active Not RecruitingTreatmentHiv-positive1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentMalignant Lymphomas2
2Active Not RecruitingTreatmentMyelodysplastic Syndrome1
2Active Not RecruitingTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentRecurrent Oral Cavity Adenoid Cystic Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Adenoid Cystic Carcinoma / Stage III Major Salivary Gland Cancer AJCC v7 / Stage III Major Salivary Gland Carcinoma / Stage III Oral Cavity Adenoid Cystic Carcinoma / Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Oral Cavity Adenoid Cystic Carcinoma / Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Oral Cavity Adenoid Cystic Carcinoma / Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Oral Cavity Adenoid Cystic Carcinoma / Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 / Tongue Carcinoma1
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdenocarcinoma of the Colon / Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2CompletedTreatmentAdenocarcinoma, Prostate / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2CompletedTreatmentAdult Acute Erythroid Leukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Recurrent Adult Acute Myeloid Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Brain Tumors / Malignant Gliomas / Recurrent Glioblastoma Multiforme1
2CompletedTreatmentAdult Favorable Prognosis Hodgkin Lymphoma / Adult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Adult Unfavorable Prognosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor2
2CompletedTreatmentCancer, Advanced1
2CompletedTreatmentCancer, Breast2
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IV Melanoma / Uveal Melanoma1
2CompletedTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma1
2CompletedTreatmentInsular Thyroid Cancer / Recurrent Thyroid Cancer / Stage II Follicular Thyroid Cancer / Stage II Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer / Thyroid Gland Medullary Carcinoma1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRecurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Indolent Adult Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma1
2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentRecurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentRenal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2CompletedTreatmentSickle Cell Disorders1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentMycosis Fungoides (MF)1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeuroblastomas1
2SuspendedTreatmentMyelodysplastic Syndrome1
2SuspendedTreatmentOcular Melanoma With Extraocular Extension / Recurrent Uveal Melanoma / Stage IV Uveal Melanoma1
2TerminatedBasic ScienceBreast Cancer Invasive Nos / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage III Breast Cancer1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
2TerminatedTreatmentBlood Diseases / Bone Marrow Diseases / Myelodysplastic Syndromes1
2TerminatedTreatmentBrain Metastasis1
2TerminatedTreatmentCancer, Breast / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentCutaneous T-cell Lymphoma Stage I / Cutaneous T-cell Lymphoma Stage II / Cutaneous T-cell Lymphoma Stage III / Cutaneous T-cell Lymphoma Stage IV1
2TerminatedTreatmentFollicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndrome1
2TerminatedTreatmentLocalized Transitional Cell Cancer of the Renal Pelvis and Ureter / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Transitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMantle Cell Lymphoma (MCL)1
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV)1
2Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Unknown StatusTreatmentParanasal Sinus Squamous Cell Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Oral Cavity Squamous Cell Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Stage IVA Hypopharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Hypopharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVC Hypopharyngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Oral Cavity Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma1
2WithdrawnTreatmentMultiple Myeloma (MM)2
2WithdrawnTreatmentNon-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentPlasma Cell Myeloma1
2, 3CompletedTreatmentBrain Stem Gliomas / Cerebral Astrocytoma / Childhood Cerebellar Anaplastic Astrocytoma / Childhood Cerebral Anaplastic Astrocytoma / Childhood Spinal Cord Neoplasm / Untreated Childhood Brain Stem Glioma / Untreated Childhood Cerebral Astrocytoma1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3TerminatedTreatmentStage IIIB or IV Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentLung Cancers / Mesothelioma1
3CompletedTreatmentMultiple Myeloma (MM)1
3WithdrawnTreatmentMalignant Lymphomas1
Not AvailableActive Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer2
Not AvailableActive Not RecruitingTreatmentMedulloblastomas / Pinealoblastoma / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableCompletedDiagnosticAdult Glioblastoma / Depression / Recurrent Adult Brain Tumor1
Not AvailableCompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage III Breast Cancer1
Not AvailableNo Longer AvailableNot AvailableLymphoma, T-Cell, Cutaneous1
Not AvailableUnknown StatusBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableWithdrawnTreatmentStage II Breast Cancer / Stage IIIA Breast Cancer / Triple-Negative Breast Cancer (TNBC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral100 mg/1
Prices
Unit descriptionCostUnit
Zolinza 100 mg capsule83.11USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6087367No1994-10-042011-10-04Us
CA2120619No2006-11-212012-10-05Canada
US7399787No2005-02-092025-02-09Us
US7732490No2003-03-042023-03-04Us
US7851509No2004-02-212024-02-21Us
US8067472No2003-03-042023-03-04Us
US8101663No2003-03-042023-03-04Us
US8450372No2008-03-182028-03-18Us
US7456219No2007-03-112027-03-11Us
US8093295No2006-05-162026-05-16Us
USRE38506No1995-07-072015-07-07Us
US7652069No2003-03-042023-03-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa9.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0716 mg/mLALOGPS
logP1.88ALOGPS
logP2ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)8.91ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity73.81 m3·mol-1ChemAxon
Polarizability28.39 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8458
Blood Brain Barrier+0.9861
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6928
P-glycoprotein inhibitor INon-inhibitor0.8741
P-glycoprotein inhibitor IINon-inhibitor0.9317
Renal organic cation transporterNon-inhibitor0.9169
CYP450 2C9 substrateNon-substrate0.8437
CYP450 2D6 substrateNon-substrate0.8345
CYP450 3A4 substrateNon-substrate0.6536
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9084
CYP450 2D6 inhibitorNon-inhibitor0.9204
CYP450 2C19 inhibitorNon-inhibitor0.88
CYP450 3A4 inhibitorNon-inhibitor0.9347
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9336
Ames testAMES toxic0.7891
CarcinogenicityNon-carcinogens0.7278
BiodegradationNot ready biodegradable0.8297
Rat acute toxicity1.9954 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9603
hERG inhibition (predictor II)Non-inhibitor0.8674
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-Hybrid FT , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001l-9750000000-d26ffebbce9b1bc73b92

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Monocyclic benzene moiety / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidic acid derivative / Carboximidic acid / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dicarboxylic acid diamide, hydroxamic acid (CHEBI:45716)

Targets

Details
1. Histone deacetylase 1
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transcription regulatory region sequence-specific dna binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC1
Uniprot ID
Q13547
Uniprot Name
Histone deacetylase 1
Molecular Weight
55102.615 Da
References
  1. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [PubMed:17694093]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Histone deacetylase 2
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC2
Uniprot ID
Q92769
Uniprot Name
Histone deacetylase 2
Molecular Weight
55363.855 Da
References
  1. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [PubMed:17694093]
Details
3. Histone deacetylase 3
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4), and some other non-histone substrates. Histone deacetylation gives a tag for ...
Gene Name
HDAC3
Uniprot ID
O15379
Uniprot Name
Histone deacetylase 3
Molecular Weight
48847.385 Da
References
  1. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [PubMed:17694093]
Details
4. Histone deacetylase 6
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC6
Uniprot ID
Q9UBN7
Uniprot Name
Histone deacetylase 6
Molecular Weight
131418.19 Da
References
  1. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007 Aug 13;26(37):5541-52. [PubMed:17694093]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC8
Uniprot ID
Q9BY41
Uniprot Name
Histone deacetylase 8
Molecular Weight
41757.29 Da
Kind
Protein
Organism
Aquifex aeolicus (strain VF5)
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Not Available
Gene Name
acuC1
Uniprot ID
O67135
Uniprot Name
Acetoin utilization protein
Molecular Weight
42662.46 Da

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33